Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.

Autor: Kang Y; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA. yubin.kang@duke.edu., Sundaramoorthy P; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA., Gasparetto C; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA., Feinberg D; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA., Fan S; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA., Long G; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA., Sellars E; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA., Garrett A; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA., Tuchman SA; Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA., Reeves BN; Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA., Li Z; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA., Liu B; Division of Hematology, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Ogretmen B; Department of Biochemistry and Molecular Biology, and Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA., Maines L; Apogee Biotechnology Corporation, Hummelstown, PA, USA., Ben-Yair VK; RedHill Biopharma, Tel Aviv, Israel., Smith C; Apogee Biotechnology Corporation, Hummelstown, PA, USA., Plasse T; RedHill Biopharma, Tel Aviv, Israel.

Publikováno v: Annals of hematology [Ann Hematol] 2023 Feb; Vol. 102 (2), pp. 369-383. Date of Electronic Publication: 2022 Dec 03.

A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease

Autor: Dotan, I., Rachmilewitz, D., Schreiber, S., Eliakim, R., Woude, C.J. van der, Kornbluth, A., Buchman, A.L., Bar-Meir, S., Bokemeyer, B., Goldin, E., Maaser, C., Mahadevan, U., Seidler, U., Hoffman, J.C., Homoky, D., Plasse, T., Powers, B., Rutgeerts, P., Hommes, D., Semapimod-CD04 CD05 Investigators

Publikováno v: Gut, 59(6), 760-766
Gut, 59(6), 760-766. BMJ Publishing Group

Objective Semapimod, a small molecule known to inhibit proinflammatory cytokine activity, was studied to determine the optimal dose necessary to achieve a response in patients with moderate to severe Crohn's disease (CD). Methods A randomised, double

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d614fcd67109384afa13f402d7f77c8
https://doi.org/10.1136/gut.2009.179994

Simultaneous soft agar cloning of ascites and solid tumor specimens from patients with ovarian cancer.

Autor: Sridhar, Kasi S., Ohnuma, Takao, Plasse, Terry F., Holland, James F., Sridhar, K S, Ohnuma, T, Plasse, T F, Holland, J F

Publikováno v: Cancer (0008543X); Oct1988, Vol. 62 Issue 8, p1577-1581, 5p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.